NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund
Executive Summary
Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route.
You may also be interested in...
New Data Helps Darzalex & Zejula Switch To Routine Funding In England
Janssen and GSK have gathered the evidence needed to convince health technology assessment body NICE that their drugs can move from the Cancer Drugs Fund to routine commissioning.
UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs
Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.
Roche's Atezolizumab Gets CDF Place For Bladder Cancer
Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.